Literature DB >> 24777676

Dendritic cells: master regulators of the immune response.

Ira Mellman1.   

Abstract

Dendritic cells (DC) are responsible for initiating all antigen-specific immune responses. As such, they are the master regulators of the immune response and serve this function by linking the microbial sensing features of the innate immune system to the exquisite specificity of the adaptive response. They are exceptionally efficient at antigen presentation and also adept at generating just the right type of T cells in response to a given pathogen. Importantly, DCs also help guide the immune system to respond to foreign antigens while avoiding the generation of autoimmune responses to self. DCs are thus paradoxically important in cancer, generating both immunity and tolerance. Given their central role in controlling the immune response in patients with cancer, DCs are emerging as a critical cell type that must be considered as we come to understand basic cancer immunobiology. They should also be considered as potential targets or at least as key players in any effort intended to generate therapeutic vaccines. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24777676     DOI: 10.1158/2326-6066.CIR-13-0102

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  87 in total

Review 1.  What is the evidence for the role of TRP channels in inflammatory and immune cells?

Authors:  A Parenti; F De Logu; P Geppetti; S Benemei
Journal:  Br J Pharmacol       Date:  2016-02-18       Impact factor: 8.739

2.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

3.  Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis.

Authors:  Samuel J Landry; Daniel L Moss; Da Cui; Ryan P Ferrie; Mitchell L Fullerton; Evan A Wells; Lu Yang; Nini Zhou; Thomas Dougherty; Ramgopal R Mettu
Journal:  Viral Immunol       Date:  2017-06-14       Impact factor: 2.257

Review 4.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

Review 5.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

6.  Transplantation tolerance: the big picture. Where do we stand, where should we go?

Authors:  H Waldmann
Journal:  Clin Exp Immunol       Date:  2017-03-02       Impact factor: 4.330

7.  An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.

Authors:  Siyuan Ma; Xiaohua Chen; Quanhui Tan; Dan Li; Shenglan Dai; Shanshan Wu; Yongsheng Yu; Guoqing Zang; Zhenghao Tang
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

Review 8.  Dendritic cell vaccines for melanoma: past, present and future.

Authors:  Robert O Dillman; Gabriel I Nistor; Andrew N Cornforth
Journal:  Melanoma Manag       Date:  2016-11-29

9.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

10.  Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Authors:  Mareike Grees; Adi Sharbi-Yunger; Christos Evangelou; Daniel Baumann; Gal Cafri; Esther Tzehoval; Stefan B Eichmüller; Rienk Offringa; Jochen Utikal; Lea Eisenbach; Viktor Umansky
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.